Mendus AB (publ) (IMMU.ST)
SEK 4.8
(-3.9%)
SEK 4.8
(-3.9%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -97.84 Million SEK | 25.0% |
| 2022 | -128.67 Million SEK | -1.71% |
| 2021 | -128.27 Million SEK | -49.11% |
| 2020 | -84.25 Million SEK | 35.8% |
| 2019 | -43.21 Million SEK | -36.95% |
| 2018 | -97.78 Million SEK | -21.35% |
| 2017 | -80.62 Million SEK | -9.86% |
| 2016 | -73.32 Million SEK | -68.56% |
| 2015 | -43.54 Million SEK | -21.17% |
| 2014 | -35.5 Million SEK | -123.16% |
| 2013 | -16.1 Million SEK | -135.57% |
| 2012 | -6.83 Million SEK | -165.31% |
| 2011 | -4.29 Million SEK | 2.61% |
| 2010 | -2.64 Million SEK | -16.25% |
| 2009 | -2.27 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -36.38 Million SEK | 8.66% |
| 2024 Q2 | -36.64 Million SEK | -7.71% |
| 2023 Q3 | -22.66 Million SEK | -818.89% |
| 2023 Q4 | -42.82 Million SEK | -88.91% |
| 2023 Q2 | -2.46 Million SEK | 91.19% |
| 2023 FY | - SEK | 5.42% |
| 2023 Q1 | -28 Million SEK | 30.38% |
| 2022 Q2 | -28.09 Million SEK | -5.45% |
| 2022 Q3 | -35.88 Million SEK | -27.73% |
| 2022 FY | - SEK | -1.71% |
| 2022 Q4 | -40.22 Million SEK | -12.09% |
| 2022 Q1 | -26.64 Million SEK | 16.14% |
| 2021 Q2 | -31.27 Million SEK | 23.3% |
| 2021 Q1 | -40.78 Million SEK | -552.06% |
| 2021 FY | - SEK | -49.11% |
| 2021 Q4 | -31.77 Million SEK | -20.82% |
| 2021 Q3 | -26.29 Million SEK | 15.92% |
| 2020 Q3 | -21.63 Million SEK | 13.99% |
| 2020 Q1 | -33.86 Million SEK | 19.37% |
| 2020 FY | - SEK | 35.8% |
| 2020 Q4 | -6.25 Million SEK | 71.09% |
| 2020 Q2 | -25.15 Million SEK | 25.74% |
| 2019 Q4 | -42 Million SEK | -41.71% |
| 2019 Q1 | -29.13 Million SEK | -11.18% |
| 2019 Q2 | -33.21 Million SEK | -13.97% |
| 2019 Q3 | -29.64 Million SEK | 10.74% |
| 2019 FY | - SEK | -36.95% |
| 2018 Q2 | -19.34 Million SEK | 32.75% |
| 2018 FY | - SEK | -21.35% |
| 2018 Q1 | -28.77 Million SEK | -53.02% |
| 2018 Q4 | -26.2 Million SEK | -11.44% |
| 2018 Q3 | -23.51 Million SEK | -21.56% |
| 2017 Q3 | -21.57 Million SEK | -13.0% |
| 2017 Q1 | -20.51 Million SEK | 16.94% |
| 2017 FY | - SEK | -9.86% |
| 2017 Q4 | -18.8 Million SEK | 12.88% |
| 2017 Q2 | -19.09 Million SEK | 6.91% |
| 2016 Q1 | -9.49 Million SEK | 15.19% |
| 2016 FY | - SEK | -68.56% |
| 2016 Q4 | -24.69 Million SEK | -106.44% |
| 2016 Q3 | -11.96 Million SEK | 21.95% |
| 2016 Q2 | -15.32 Million SEK | -61.39% |
| 2015 Q4 | -11.19 Million SEK | -43.67% |
| 2015 Q1 | -10.57 Million SEK | 3.62% |
| 2015 Q2 | -7.82 Million SEK | 26.05% |
| 2015 Q3 | -7.79 Million SEK | 0.34% |
| 2015 FY | - SEK | -21.17% |
| 2014 Q1 | -5 Million SEK | -32.6% |
| 2014 FY | - SEK | -123.16% |
| 2014 Q4 | -10.97 Million SEK | -78.97% |
| 2014 Q3 | -6.13 Million SEK | -10.66% |
| 2014 Q2 | -5.54 Million SEK | -10.75% |
| 2013 Q3 | -1.78 Million SEK | 34.1% |
| 2013 FY | - SEK | -135.57% |
| 2013 Q2 | -2.7 Million SEK | -5.41% |
| 2013 Q1 | -2.56 Million SEK | -134.51% |
| 2013 Q4 | -3.77 Million SEK | -111.67% |
| 2012 Q4 | -1.09 Million SEK | 0.0% |
| 2012 Q3 | -1.09 Million SEK | 32.12% |
| 2012 Q2 | -1.61 Million SEK | 0.0% |
| 2012 Q1 | -1.61 Million SEK | 0.0% |
| 2012 FY | - SEK | -165.31% |
| 2011 FY | - SEK | 2.61% |
| 2010 FY | - SEK | -16.25% |
| 2009 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 73.397% |
| AcouSort AB (publ) | -16.7 Million SEK | -485.799% |
| Active Biotech AB (publ) | -43.88 Million SEK | -122.95% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 233072.214% |
| Amniotics AB (publ) | -27.14 Million SEK | -260.483% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -588.232% |
| BioArctic AB (publ) | 275.38 Million SEK | 135.53% |
| Camurus AB (publ) | 562.54 Million SEK | 117.393% |
| Cantargia AB (publ) | -284.31 Million SEK | 65.585% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -399.75% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -472.718% |
| Genovis AB (publ.) | 64.57 Million SEK | 251.53% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 14.848% |
| Kancera AB (publ) | -61.88 Million SEK | -58.099% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -265.329% |
| LIDDS AB (publ) | -39.67 Million SEK | -146.65% |
| Lipum AB (publ) | -37.11 Million SEK | -163.601% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -708.377% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 411.572% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 4892400.0% |
| NextCell Pharma AB | -40.98 Million SEK | -138.735% |
| OncoZenge AB (publ) | 7.26 Million SEK | 1446.628% |
| Saniona AB (publ) | -69.69 Million SEK | -40.392% |
| Simris Alg AB (publ) | -22.36 Million SEK | -337.535% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 69.179% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 65.307% |
| Xintela AB (publ) | -53.47 Million SEK | -82.989% |
| Ziccum AB (publ) | -20.34 Million SEK | -381.005% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -164.277% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 42.381% |
| CombiGene AB (publ) | -35.33 Million SEK | -176.901% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 30.532% |
| Intervacc AB (publ) | -68.98 Million SEK | -41.847% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 58.821% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -4604.135% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -628.509% |
| Corline Biomedical AB | -1.69 Million SEK | -5686.28% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 43.547% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -78.532% |
| Aptahem AB (publ) | -10 Million SEK | -877.558% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 947.225% |
| Fluicell AB (publ) | -25.91 Million SEK | -277.58% |
| Biovica International AB (publ) | -119.5 Million SEK | 18.125% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -131.731% |
| Abliva AB (publ) | -93.6 Million SEK | -4.527% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 69.337% |
| 2cureX AB (publ) | -35.13 Million SEK | -178.478% |
| I-Tech AB | 30.34 Million SEK | 422.445% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 86.307% |
| Cyxone AB (publ) | -20.41 Million SEK | -379.308% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 4.497% |
| Biosergen AB | 228 Thousand SEK | 43014.912% |
| Nanologica AB (publ) | -62.11 Million SEK | -57.514% |
| SynAct Pharma AB | -222.7 Million SEK | 56.064% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -123.082% |
| BioInvent International AB (publ) | -312.7 Million SEK | 68.71% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 31723.106% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 57.756% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -1010.312% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 9.868% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -753.135% |